Senseonics Launches Eversense 365 CGM in Europe

The diabetes technology company Senseonics has initiated the European commercial launch of the Eversense 365, marking the first availability of a one-year continuous glucose monitoring system outside the United States. The rollout begins in Sweden with additional markets scheduled for Germany, Spain, and Italy in the coming weeks.

This launch follows the company's receipt of CE Mark approval in January 2026, clearing the path for commercialization across the European Union under the EU Medical Device Regulation. The sensor represents a significant departure from the standard CGM market, where devices typically last 10-14 days before requiring replacement.

According to the official press release distributed via Globe Newswire, the Eversense 365 doubles the sensor lifespan from the previous Eversense E3 model, extending from six months to a full year. The device also reduces calibration frequency from once daily to once weekly, which translates to fewer interruptions in the patient's routine.

The physical reality of using an implantable CGM differs substantially from traditional adhesive-based systems. The tiny sensor rests under the skin, meaning it cannot be knocked off during daily activities. Users change the gentle, silicone-based adhesive daily with minimal skin reactions, though the transmitter itself can be removed and reattached without wasting the sensor or requiring a warm-up period. (There's no glucose data generated when the transmitter is removed, which is worth noting if you're swimming or showering.)

Tim Goodnow, President and Chief Executive Officer of Senseonics, stated that the European expansion increases the company's total addressable market by over 30 million patients living with diabetes in the EU. The firm is transitioning to an end-to-end commercial organization in 2026, taking full ownership of all commercial activities for Eversense 365.

Independent reporting from MassDevice confirms the launch timeline and notes the system's integrated CGM (iCGM) clearance, allowing it to work with compatible medical devices including insulin pumps as part of automated insulin delivery systems. The Sequel Med Tech twiist system is one such compatible AID platform.

The device was originally approved by the United States Food and Drug Administration in September 2024 and launched across the country in October of that same year. Real-world evidence presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2026 demonstrated sustained performance across a full year period, with patients showing improvements in A1C levels and time in target glucose range.

From a technical standpoint, the Eversense 365 addresses several pain points inherent to short-term CGM systems. Traditional sensors tend to fail early in their lifecycle, creating data gaps that frustrate users. The implantable design eliminates this failure mode while also reducing the frequency of insertions from roughly 26 times per year to just once. On-body vibration alerts keep patients notified even when their mobile phone is out of sight, which matters during sleep or when the phone is in another room.

The company expects the European expansion to contribute to top-line revenue growth while offering a differentiated solution to glucose monitoring. Brian Hansen, Chief Commercial Officer of Senseonics, noted that excitement for Eversense 365 was palpable at ATTD, with real-world evidence showcasing the device's unique benefits of delivering one year of exceptionally accurate monitoring with minimal interruptions.

Patients in these European markets can access more information through the company's website. The phased rollout approach allows Senseonics to manage distribution logistics while establishing clinical partnerships in each territory. Whether healthcare systems across Europe will reimburse for a device with higher upfront costs but lower long-term replacement frequency remains the real question.

Artūras Malašauskas is an AI Systems Integrator with 20+ years of production-grade web engineering experience. He has designed, shipped, and scaled enterprise Python/PHP systems for logistics, SaaS, and public-sector clients. For the past year, he has focused exclusively on AI integrations: deploying open-source LLMs, building generative media pipelines (image, audio, video), and engineering multi-agent workflows for real production environments. His standard: reproducibility, security, cost-efficient inference—no vaporware. He documents and evaluates emerging AI tooling, separating verified capabilities from marketing noise. Technical editor at: muza-ai.eu, ai-verslas.lt, ai-naujinos.lt Connect on LinkedIn